[Effects of proteolytic enzymes on advanced glycation end-products (AGEs): possible clinical implications].
Heidland
A
A
Medizinische Klinik der Universität Würzburg, Würzburg. August.Heidland@t-online.de
Stopper
H
H
Schupp
N
N
Paczek
L
L
Klassen
A
A
Sebeková
K
K
D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D004249:DNA Damage / Q000502:physiology; D048909:Diabetes Complications / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D051379:Mice; D023421:Models, Animal; D010447:Peptide Hydrolases / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D016212:Transforming Growth Factor beta / Q000378:metabolism
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D017127:Glycation End Products, Advanced; D016212:Transforming Growth Factor beta; D010447:Peptide Hydrolases